(Q35562290)

8 August 2017

1 reference

title

Introducing vedolizumab to clinical practice: who, when, and how? (English)

1 reference

8 August 2017

author

William Jeffery Sandborn

series ordinal

2

object named as

W J Sandborn

1 reference

8 August 2017

R V Bryant

1

1 reference

8 August 2017

S P L Travis

series ordinal

3

1 reference

8 August 2017

publication date

16 February 2015

1 reference

Journal of Crohn's and Colitis

8 August 2017

published in

1 reference

8 August 2017

volume

9

1 reference

8 August 2017

issue

4

1 reference

8 August 2017

page(s)

356-366

1 reference

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Vedolizumab as induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Vedolizumab as induction and maintenance therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

The pattern and outcome of acute severe colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Colon cancer screening and surveillance in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Development of the Crohn's disease digestive damage score, the Lémann score

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Ulcerative colitis as a progressive disease: the forgotten evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

The natural history of adult Crohn's disease in population-based cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Vedolizumab for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Review article: anti-adhesion therapies for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients With Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJV033

21 January 2018

Identifiers

DOI

10.1093/ECCO-JCC/JJV033

1 reference

8 August 2017

1 reference